VOLITIONRX LTD (VNRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 406,688 | 246,385 | 474,522 | 395,797 |
| Sales and marketing | 1,043,534 | 917,299 | 1,053,584 | 1,386,378 |
| Research and development | 2,720,207 | 2,607,444 | 3,473,782 | 3,715,797 |
| General and administrative | 2,940,754 | 2,243,362 | 1,815,863 | 2,284,041 |
| Total operating expenses | 6,704,495 | 5,768,105 | 6,343,229 | 7,386,216 |
| Operating loss | -6,297,807 | -5,521,720 | -5,868,707 | -6,990,419 |
| Gain (loss) on change in fair value of warrant liability | -62,764 | 20,038 | - | - |
| Grant income | 75,991 | 121,566 | 85,378 | - |
| Interest income | 160 | 158 | 530 | 450 |
| Interest expense | 123,356 | 96,669 | 89,456 | 81,182 |
| Gain (loss) on disposal of fixed assets | 330 | - | -1,195 | -33,498 |
| Gain on change in fair value of derivative liability | 418,681 | - | 4,872 | 44,474 |
| Amortization of debt discount | 325,305 | - | - | - |
| Total other income (expenses) | -16,263 | 45,093 | 129 | -69,756 |
| Net loss | -6,314,070 | -5,476,627 | -5,868,578 | -7,060,175 |
| Net loss attributable to non-controlling interest | 29,992 | - | - | - |
| Net loss attributable to non-controlling interest | - | -52,868 | -47,049 | 74,629 |
| Net loss attributable to volitionrx limited stockholders | -6,284,078 | -5,423,759 | - | - |
| Foreign currency translation adjustments | -575,996 | - | - | - |
| Net income (loss) available to common stockholders, basic | - | - | -5,821,529 | -6,985,546 |
| Foreign currency translation adjustments | - | - | -141,980 | 23,286 |
| Net comprehensive loss | -6,890,066 | -5,423,759 | -6,010,558 | -7,036,889 |
| Basic & diluted eps | - | - | -0.07 | -0.08 |
| Net loss per share - basic and diluted attributable to volitionrx limited stockholders | -0.06 | -0.06 | - | - |
| Weighted average shares outstanding- basic and diluted | 102,654,095 | 96,536,052 | - | - |